850544-26-2

Basic information

• Product Name: 4,6-Dichloro-5-nitro-2-pyridinecarboxylic acid
• Synonyms: 4,6-Dichloro-5-nitro-2-pyridinecarboxylic acid;2,4-dichloro-3-nitropyridine-6-carboxylic acid
• CAS NO: 850544-26-2
• Molecular Formula: C₆H₂Cl₂N₂O₄
• Molecular Weight: 236.99708
• Mol File: 850544-26-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 137-139 °C
• Boiling Point: 421.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.810±0.06 g/cm3(Predicted)
• PKA: 1.97±0.13(Predicted)
• CAS DataBase Reference: 4,6-Dichloro-5-nitro-2-pyridinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloro-5-nitro-2-pyridinecarboxylic acid(850544-26-2)
• EPA Substance Registry System: 4,6-Dichloro-5-nitro-2-pyridinecarboxylic acid(850544-26-2)

Safety Data

• Hazardous Substances Data: 850544-26-2(Hazardous Substances Data)

Upstream product

• 4966-90-9 2,4-Dihydroxy-6-methyl-3-nitropyridine 
• 63897-12-1 2,4-dichloro-6-methyl-3-nitropyridine 

Downstream Products

• 1314945-22-6 (R)-7-(3-aminopiperidin-1-yl)-1-(2-cyanobenzyl)-3-methyl-5-formyloxy-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride 
• 1392444-16-4 C₂₁H₂₃N₇O₂ 
• 1314945-20-4 (R)-2-[[7-(3-aminopiperidin-1-yl)-3-methyl-5-hydroxymethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile 
• 1314947-55-1 (R)-7-(3-tert-butoxycarbonylaminopiperidin-1-yl)-1-(2-cyanobenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-5-formylic acid 
• 1392444-63-1 C₂₆H₃₁N₇O₄ 
• 1314947-53-9 (R)-1-[1-(2-cyanobenzyl)-3-methyl-5-hydroxymethyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl]piperidine-3-carbamic acid tert-butyl ester 
• 1314947-51-7 (R)-7-(3-tert-butoxycarbonylaminopiperidin-1-yl)-1-(2-cyanobenzyl)-3-methyl-5-methoxycarbonyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine 

Relevant articles and documents

GLP-1R AGONISTS AND USES THEREOF

Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

Discovery of imigliptin, a novel selective DPP-4 inhibitor for the treatment of type 2 diabetes

We report our discovery of a novel series of potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Starting from a lead identified by scaffold-hopping approach, our discovery and development efforts were focused on exploring structure-activity relationships, optimizing pharmacokinetic profile, improving in vitro and in vivo efficacy, and evaluating safety profile. The selected candidate, Imigliptin, is now undergoing clinical trial.

FUSED PYRIDINE DERIVATIVES

Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R1, R2, R3, Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.